Alentis Strengthens Management Team with Key Appointments

Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan Yoon as General Counsel and Chief Administrative Officer, and Aditya Venugopal as Chief Business Officer. Mr. Yoon and Dr. Venugopal are joining Alentis’ executive leadership team.

“We are expanding our corporate capabilities as we gear up for significant near-term inflection points, with key clinical data readouts in our fibrosis and oncology programs expected next year,” said Dr. Mark Pruzanski, CEO of Alentis. “It is terrific to be working again with Bryan and Aditya whose knowledge and experience will be of great value to the team and the company’s prospects.”

Bryan Yoon has over 20 years of experience working with life sciences companies, most recently serving as Chief Operating Officer and General Counsel at Terns Pharmaceuticals, where he led corporate strategy, business development, and company operations, and was instrumental in its successful transition to a publicly traded company. Prior to Terns, Mr. Yoon held various executive leadership positions at LogicBio Therapeutics, Nightstar Therapeutics (acquired by Biogen in 2019), and Intercept Pharmaceuticals. Earlier in his career, Mr. Yoon advised biopharmaceutical companies as an attorney at Mintz Levin and Simpson Thacher & Bartlett. Mr. Yoon received his J.D. from the University of Michigan Law School.

Aditya Venugopal has over 15 years of experience in the life sciences industry, most recently as Head of Corporate Development and Operations at Versanis Bio, where he was instrumental in scaling operations, securing investor funding, and driving the M&A process that led to the company’s acquisition by Eli Lilly and Company. Prior to joining Versanis, Dr. Venugopal led Business Development at VectivBio until its acquisition by Ironwood Pharmaceuticals, and before that he held several senior leadership roles at Intercept Pharmaceuticals, including Head of Strategic Planning. Dr. Venugopal began his career as a strategic life sciences consultant at Easton Associates and Navigant Consulting. He holds a Ph.D. in Immunology and Microbial Pathogenesis from Cornell’s Weill Medical School.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Albert Baines today!